Leqvio Travel & Timezone-Shift Protocols: Complete Clinical Guide

Does a time zone change affect a Leqvio dose?

No. Inclisiran has no daily dosing, so there is no time of day to move when a flight shifts the clock by 6 or 12 hours. The label writes the schedule in months: 284 mg subcutaneously initially, again at 3 months, then every 6 months, administered by a healthcare professional [1]. What matters is the date of the appointment.

How late can a Leqvio dose be given?

The label's missed-dose rule is stated in months [1]:

• If a planned dose is missed by less than 3 months, the dose is given and dosing continues according to the patient's original schedule.
• If a planned dose is missed by more than 3 months, the schedule restarts: initial dose, again at 3 months, then every 6 months.

A dose that falls during a two-week trip and is delayed by a few weeks sits inside the first branch.

What the pharmacology shows about the gap between doses

Inclisiran is a small interfering RNA that the liver takes up and uses to direct breakdown of PCSK9 messenger RNA, which raises LDL receptor recycling and lowers circulating LDL-C [1]. It is not a statin and not a monoclonal antibody.

After a single 284 mg dose, LDL-C reduction was apparent within 14 days [1]. After doses on Day 1 and Day 90, mean serum PCSK9 fell by about 75% at Day 120 and 69% at Day 180 [1]. The label notes that LDL-C lowering persists for months after a dose even though the plasma half-life is about 9 hours [1].

Does the patient carry Leqvio or keep it cold?

The label says Leqvio should be administered by a healthcare professional, injected into the abdomen, upper arm or thigh [1]. It is stored at room temperature, 20 to 25 C (68 to 77 F), with no refrigeration [1].

What to watch for after an injection, including on a travel day

The most common reaction is local. In pooled adult placebo-controlled trials (1,833 patients on Leqvio, 1,822 on placebo), injection site reaction occurred in 8% versus 2%, arthralgia in 5% versus 4%, and bronchitis in 4% versus 3%; adverse reactions led to discontinuation in 2.5% versus 1.9% [1]. The label says not to inject into areas of active skin disease or injury, such as sunburns, skin rashes, inflammation or skin infections [1].

Hypersensitivity is the only Warning and Precaution in the label [1]. Anaphylaxis and angioedema have been reported with Leqvio, and the label says to advise patients on the signs and symptoms and to instruct them to seek medical attention promptly [1]. A prior serious hypersensitivity reaction to inclisiran or any excipient is a contraindication [1].

Other medicines during travel

No formal clinical drug interaction studies were done with inclisiran [1]. It is not a substrate, inhibitor or inducer of cytochrome P450 enzymes or transporters, and it is not expected to cause or be affected by CYP or transporter interactions; a population pharmacokinetic analysis found no clinically significant change in atorvastatin or rosuvastatin concentrations [1]. The label lists no specific interacting drug [1].

Patients in the two pivotal trials were enrolled while taking a maximally tolerated statin [4].

The trials behind the six-month schedule

ORION-10 enrolled 1,561 adults with atherosclerotic cardiovascular disease and ORION-11 enrolled 1,617 adults with ASCVD or a risk equivalent; both compared inclisiran 284 mg with placebo on day 1, day 90, then every 6 months [4]. At day 510, LDL-C fell by 52.3% in ORION-10 and 49.9% in ORION-11 relative to placebo [4]. Neither trial was designed to show a reduction in cardiovascular events [4].